Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease by Cook, Andrew D et al.
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
R
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
Research article
Blockade of collagen-induced arthritis post-onset by antibody to
granulocyte-macrophage colony-stimulating factor (GM-CSF):
requirement for GM-CSF in the effector phase of disease
Andrew D Cook, Emma L Braine, Ian K Campbell*, Melissa J Rich and John A Hamilton
Arthritis and Inflammation Research Centre, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
*Current address: Autoimmunity and Transplantation Division, The Walter and Eliza Hall Institute, Parkville, Victoria, Australia
Correspondence: Dr Andrew Cook, Arthritis and Inflammation Research Centre, Department of Medicine, University of Melbourne, Victoria 3010,
Australia. Tel: +61 3 8344 6252; fax: +61 3 9347 1863; e-mail: adcook@unimelb.edu.au
Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory
disease characterized by the presence of numerous inflam-
matory mediators and the destruction of diarthrodial joints.
GM-CSF was initially discovered for its role in the differen-
tiation of hemopoietic precursor cells into mature granulo-
cytes and macrophages [1]; however, it can also affect
mature cell function and may be considered pro-
inflammatory [2,3]. There is some evidence to suggest that
GM-CSF may play a role in the pathogenesis of RA [4–6].
CIA is a commonly used model for RA, with which it has
many immunologic and pathologic parallels [7]. In the
present study, we examined the temporal requirement for
Abstract
There is mounting evidence for a role of the growth factor granulocyte-macrophage colony-stimulating
factor (GM-CSF) in inflammatory disease, including arthritis. In the present study, we examined the
effectiveness of treatment of collagen-induced arthritis (CIA) with a neutralizing mAb to GM-CSF.
DBA/1 mice were immunized for the development of CIA and treated at different times, and with
different doses, with neutralizing mAb to GM-CSF or isotype control mAb. Anti-GM-CSF mAb
treatment prior to the onset of arthritis, at the time of antigen challenge, was effective at ameliorating
the ensuing disease. Modulation of arthritis was seen predominantly as a reduction in overall disease
severity, both in terms of the number of limbs affected per mouse and the clinical score of affected
limbs. Importantly, anti-GM-CSF mAb treatment ameliorated existing disease, seen both as a reduction
in the number of initially affected limbs progressing and lower numbers of additional limbs becoming
affected. By histology, both inflammation and cartilage destruction were reduced in anti-GM-CSF-
treated mice, and the levels of tumor necrosis factor-α and IL-1β were also reduced in joint tissue
washouts of these mice. Neither humoral nor cellular immunity to type II collagen, however, was
affected by anti-GM-CSF mAb treatment. These results suggest that the major effect of GM-CSF in
CIA is on mediating the effector phase of the inflammatory reaction to type II collagen. The results also
highlight the essential role of GM-CSF in the ongoing development of inflammation and arthritis in CIA,
with possible therapeutic implications for rheumatoid arthritis.
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GM-CSF in CIA by treating mice with a neutralizing mAb.
The findings show that anti-GM-CSF mAb treatment can
ameliorate arthritis not only when given prior to disease
onset, but also post-onset.
Materials and methods
Collagen-induced arthritis
Male DBA/1 mice (ARC, Canning Vale, Western Australia,
Australia), were immunized for CIA as previously described
[8–11] (see Supplementary material). Mice were scored
for arthritis using a scale of 0 (normal) to 3 (joint distortion
and/or rigidity) for each limb. Antibodies to type II collagen
(CII) were measured in serum by ELISA [9].
Paraffin-embedded sections of rear limbs were evaluated
for infiltration of cells, cartilage damage and bone erosions
(H & E stain), all scored separately from 0 (normal) to 3
(severe). Proteoglycan loss was also evaluated (safranin
O, fast green stain), and scored from 0 (normal) to 3
(complete loss of staining) [12]. These scores were
summed to give an overall histologic score out of 12.
mAb treatment
Neutralizing anti-mouse GM-CSF mAb (22E9.11 [13]; Dr
J. Abrams, DNAX Research Institute, Palo Alto, CA, USA)
and isotype control mAb (GL117.41; DNAX Research
Institute) were purified on a protein G-sepharose column.
Mice were treated intraperitoneally (i.p.) with 300 µg of
the appropriate mAb at different times (see Results and
Supplementary material).
T-cell proliferation assay
Cells from inguinal lymph nodes were isolated from mice
treated with mAb, and the proliferative response to CII
was measured by [3H]thymidine incorporation [10] (see
Supplementary material).
Cytokine ELISAs
Following sacrifice on day 35 after immunization, the
tendons and synovium from the ankle joints of the hind
limbs were dissected free from the surrounding tissue,
cytokines were eluted for 1 hour at room temperature and
supernatants were collected [14]. GM-CSF, tumor necro-
sis factor-α (TNFα) and IL-1β levels were measured in
ankle joint tissue washouts and serum by ELISA (see Sup-
plementary material).
Statistics
The Mann–Whitney two-sample rank test was used for dif-
ferences in clinical and histologic scores, cytokine and
anti-CII levels, and T-cell proliferation between treatment
groups. The Spearman correlation coefficient was used
for correlations, and the chi-squared test or two-way analy-
sis of variance was used for differences in the number,
clinical score and histologic features of individual limbs.
P ≤ 0.05 was considered significant.
Results
GM-CSF blockade prior to onset of arthritis results in
less severe disease
Mice were treated i.p. with increasing doses of anti-GM-
CSF (30, 100, and 300 µg) beginning at day 21, and then
every second day until day 31. Control mice received the
highest dose (300 µg) of control mAb. There was a dose-
related suppression of the clinical score, with mice receiv-
ing 300 µg anti-GM-CSF mAb showing a marked
reduction of disease (Fig. 1a). This decrease in severity
was seen both as a reduction in the number of affected
limbs per mouse and as lower clinical scores for these
affected limbs (see Supplementary Fig. 1). However, while
there was a trend towards a lower incidence of arthritis
with increasing doses of anti-GM-CSF mAb, this did not
reach significance (Fig. 1b).
Decreasing the number of treatments resulted in a reduced
effect on disease outcome (see Supplementary Fig. 2a).
Anti-GM-CSF mAb treatment before the booster injection
(day 21), when the CII-specific immune response was
developing, had no significant effect on disease (see Sup-
plementary Fig. 2b,c).
Figure 1
Effect of anti-GM-CSF treatment prior to the onset of arthritis. (a)
Severity (mean clinical scores ± SEM). (b) Cumulative incidence. Mice
were treated intraperitoneally every second day from days 21 to 31
with anti-GM-CSF mAb or control mAb. * P = 0.05 and ** P = 0.01
compared with control mAb-treated. GM-CSF, Granulocyte
macrophage-colony stimulating factor; mAb, monoclonal antibody.
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*GM-CSF blockade prevents the clinical progression of
established arthritis
After observing that anti-GM-CSF could be beneficial
when given appropriately prior to the onset of clinical
arthritis, its therapeutic effect was sought by beginning
treatment after the onset of clinical arthritis. Once mice
had clinical signs of inflammation they were paired accord-
ing to their arthritic score and assigned to either the anti-
GM-CSF mAb or control mAb treatment group. Mice were
treated i.p. daily (300 µg) from the day of disease onset
(day 0) to day 9 after onset (i.e. a total of 10 times).
Mice injected with anti-GM-CSF mAb showed no major
progression of disease, with the mean clinical score not
significantly different on day 10 compared with day 0
(disease onset) (2.8 ± 0.4 versus 1.9 ± 0.2, respectively;
P > 0.05) (Fig. 2). Control mAb-treated mice, in contrast,
showed typical disease progression with a significantly
higher mean clinical score on day 10 compared with day 0
(5.4 ± 0.7 versus 1.9 ± 0.2, respectively; P = 0.0001)
(Fig. 2). Anti-GM-CSF mAb-treated mice thus developed
significantly milder disease than control mAb-treated mice
(day 10, 2.8 ± 0.4 versus 5.4 ± 0.7; P = 0.007). There
was no increase in the severity of arthritis following cessa-
tion of treatment with either mAb (day 10) (Fig. 2).
This absence of disease progression was seen as a rela-
tive lack of an increase in the clinical score of initially
affected limbs following anti-GM-CSF treatment. Further-
more, anti-GM-CSF-treated mice showed a diminished
recruitment of additional limbs that were normal at the
commencement of treatment (see Supplementary Fig. 3).
Reduced histopathology of joints following GM-CSF
blockade
Both inflammation and joint destruction are aspects of
arthritis, and while treatment may alleviate one aspect (e.g.
inflammation) it may have no effect on another (e.g. joint
destruction) [12]. The histologic features of infiltration, car-
tilage damage, proteoglycan depletion and bone erosions
were lower in anti-GM-CSF mAb-treated mice compared
with control mAb-treated mice (P < 0.0001, two-way analy-
sis of variance; data not shown). The mean total score for
the anti-GM-CSF mAb-treated group was significantly
lower than for control mAb-treated mice when the histo-
logic scores for each feature were combined for each
treatment group (3.7 ± 0.5 versus 5.9 ± 0.8; P = 0.03).
Figure 3 shows a normal joint and representative joints
from arthritic mice following treatment with either control
mAb or anti-GM-CSF mAb. There is less cellular infiltration
and cartilage destruction in the anti-GM-CSF mAb-treated
mouse compared with the control-treated mouse, in paral-
lel with the reduction in clinical score.
Humoral and cellular response to CII following GM-CSF
blockade in vivo
CIA development is dependent on a B-cell and T-cell
response [10,15], and GM-CSF is implicated in the devel-
opment of antigen presenting cells [16]. Treatment with
anti-GM-CSF mAb had no effect on the anti-CII IgG
response, nor the proliferative response of T cells to CII
(see Supplementary Fig. 4).
Reduced cytokine levels in joint tissues following 
GM-CSF blockade in vivo
GM-CSF was only detectable in the joint washouts of mice
with arthritis. Levels tended to be lower in anti-GM-CSF
mAb-treated mice than control mAb-treated mice (Fig. 4).
There was also a significant reduction in the mean levels of
both TNFα and IL-1β in the joint washouts for anti-GM-CSF
mAb-treated mice compared with control mAb-treated mice
(P = 0.02 and P = 0.007, respectively) (Fig. 4).
None of the cytokines could be detected in the serum of
any of the mice at any time point measured for the various
treatment regimes (data not shown).
Discussion
There is mounting evidence for a role of GM-CSF in
inflammatory disease, including arthritis. In the present
study, we confirm the essential role of GM-CSF in
ongoing development of inflammation and arthritis in CIA
using a neutralizing mAb that blocks GM-CSF. We show
that it is not only possible to ameliorate arthritis when
treated prior to onset of clinical disease at the time of
antigen challenge but, importantly, arthritis is also reduced
in mice with established disease. Treatment of established
disease is what is required of a therapeutic agent for RA.
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Figure 2
Effect of anti-GM-CSF treatment on established arthritis. Mice were
treated daily (days 0–9) with anti-GM-CSF mAb or control mAb.
Results are expressed as the mean ± SEM (P =0.007). GM-CSF,
Granulocyte macrophage-colony stimulating factor; mAb, monoclonal
antibody.
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7We have previously shown that injection of GM-CSF exac-
erbates CIA [8], while GM-CSF gene-deficient mice are
essentially resistant to CIA [9].
The apparent importance of timing for the effectiveness of
anti-GM-CSF mAb treatment provides insight into the role
that GM-CSF might play in the pathogenesis of arthritis.
The fact that the antibody and cellular proliferative
responses to CII were not reduced by anti-GM-CSF
administration, and the lack of evidence so far for subse-
quent disease suppression if administered prior to antigen
challenge, at least with the protocols tried, suggest that
GM-CSF is involved in later events associated with the
effector phase. Such events are subsequent to T-cell acti-
vation, and most probably effect mediators of inflammation
(e.g. cytokines).
In keeping with the decrease in disease severity following
anti-GM-CSF mAb treatment, we found the mean levels of
TNFα and IL-1β were reduced in ankle joint washouts of
anti-GM-CSF mAb-treated mice. These reduced levels
correlated with disease severity and suggest that GM-
CSF plays an important role in the local expression of the
Arthritis Research    Vol 3 No 5 Cook et al
Figure 3
Effect of anti-GM-CSF treatment post-onset on joint histopathology of hind-limb distal interphalangeal joints with CIA. (a), (b) Normal joint; 
(c), (d) joint from a control mAb-treated mouse; and (e), (f) joint from an anti-GM-CSF mAb-treated mouse. For control and anti-GM-CSF
mAb-treated mice, both limbs had a clinical score of 1 at onset. The control mAb-treated mouse limb progressed to a score of 3, whereas the
anti-GM-CSF mAb-treated mouse limb showed no change over the course of treatment. These results are representative for each treatment group.
(c) Severe inflammation and joint destruction is shown compared with (a). (e) Only mild infiltration and damage is evident with the architecture of
the joint remaining intact. This is also reflected in (d), where there is loss of proteoglycan staining (arrowheads) compared with (b), while (f) shows
intermediate staining. (a), (c) and (e) H & E staining; (b), (d) and (f) Safranin O, fast green staining. Magnification, x 125. B, Bone; C, cartilage; CIA,
collagen-induced arthritis; GM-CSF, granulocyte macrophage-colony stimulating factor; J, joint space; M, bone marrow; mAb, monoclonal antibody.
Figure 4
Effect of anti-GM-CSF treatment on cytokine levels in the joints.
GM-CSF, TNFα and IL-1β levels were measured by enzyme-linked
immunosorbent assay in washouts from ankle joints of arthritic mice for
mice treated with anti-GM-CSF or control mAb every second day from
days 21 to 31 post immunization. Results are expressed as the mean
level ± SEM (pg/ml). *P = 0.02 and **P = 0.007 compared with
control mAb-treated mice. GM-CSF, Granulocyte macrophage-colony
stimulating factor; IL-1β, interleukin-1β; mAb, monoclonal antibody;
TNFα, tumor necrosis factor-α.
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controlmacrophage-derived TNFα and IL-1β, two key mediators
in inflammatory joint disease. There is both in vitro and in
vivo evidence for GM-CSF having a number of proinflam-
matory effects on both monocytes/macrophages and
granulocytes [2,3,17–24], including priming of human
monocytes for subsequent cytokine production.
GM-CSF may also be acting systemically because i.p.
administration of anti-GM-CSF mAb largely prevented
the spread of disease to new limbs. While it was not
possible to measure serum GM-CSF levels, due to the
short half-life of GM-CSF [25], this does not rule out a
possible systemic role.
At sites of inflammation, including joints, GM-CSF has
been proposed to form part of an inflammatory cytokine-
driven feedback cascade termed the ‘CSF network’
[26–30]. Our predictions from this model are that exoge-
nous GM-CSF will potentiate inflammatory disease and
that it will be a therapeutic target — there is now evidence
for both these hypotheses. By blocking GM-CSF, fewer
primed macrophages (and granulocytes) would thus be
present at a site of inflammation, as evidenced by the
current study, with the result that less mediators would be
produced to promote inflammation and tissue destruction.
Conclusion
Experimental data indicating suppression of CIA by anti-
TNFα antibody treatment preceded successful TNFα tar-
geting in RA [12,31]. The present data show that
anti-GM-CSF mAb treatment also suppresses CIA and, in
particular, that existing disease can be ameliorated. These
results suggest that the major effect of GM-CSF in CIA is
in mediating the effector phase of the inflammatory reac-
tion to CII. Both the inflammatory and erosive processes
are affected, and the levels of key proinflammatory
cytokines in RA, TNFα and IL-1β, are reduced, suggesting
that consideration be likewise given to modulating GM-
CSF clinically for inflammatory conditions.
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Supplementary material
Materials and methods
Collagen-induced arthritis
Male DBA/1 mice, 8–12 weeks old (ARC, Canning Vale,
WA, USA) were immunized intradermally in the base of
the tail with 100 µg chick CII (Sigma, St. Louis, MO, USA)
emulsified in an equal volume of complete Freund’s adju-
vant containing 5 mg/ml heat-killed Mycobacterium tuber-
culosis (H37 Ra; Difco, Detroit, MI, USA). This procedure
was repeated as a boost 21 days later, as previously pub-
lished [8–11].
mAb treatment
Mice were treated i.p. with 300 µg of the appropriate mAb
in a volume of 100 µl at various times. The first treatment
was prior to the clinical onset of arthritis at the time of
primary immunization (day 0), either once or at weekly
intervals from days 0 to 21. Another treatment occurred at
the time of antigen challenge (day 21), either once, twice
(days 21 and 23), or every second day from days 21 to
31. For the latter regime, 30 and 100 µg anti-GM-CSF
mAb were also used. The final time for treatment was fol-
lowing clinical onset of arthritis. For treatment of existing
arthritis, mAb was administered daily for a total of 10 days
following onset of arthritis. Mice were paired according to
their arthritic score and then assigned to either the anti-
GM-CSF mAb treatment group or the isotype control mAb
treatment group, such that both groups had approximately
the same clinical score (mean ± SEM) on the first day of
mAb administration (day 0).
T-cell proliferation assay
Cells from inguinal lymph nodes were isolated from mice
treated every second day with 300 µg of mAb from days
21 to 31. These cells were cultured (5 × 105 cells/well,
2–3 mice/group), for 72 hours at 37°C (5% CO2), with
0–100 µg/ml denatured CII (boiled for 10 min) in RPMI
containing 50 µM 2-ME and 5% (v/v) fetal calf serum
(200 µl/well) [10]. Either anti-GM-CSF mAb or isotype-
control mAb were added to selected wells at concentra-
tions of 100 µg/ml. Cells were pulsed with 1 µCi [3H]TdR
(Amersham Int., Amersham, UK) 16 hours prior to harvest-
ing. Cells were harvested using an Inotech cell harvester
(Inotech Biosystems International Inc, Rockville, MD, USA)
and DNA synthesis measured by [3H]TdR incorporation
using a Beckman β scintillation counter (Beckman Instru-
ments Inc., Irvine, CA, USA). Results are expressed as a
Stimulation Index where cells cultured in media alone have
an index of 1.
Cytokine ELISAs
The coating and capture antibodies, respectively, used in
the cytokine ELISAs were anti-GM-CSF mAb (22E9.11;
DNAX [13]) and a biotinylated anti-GM-CSF mAb
(31G6.41; Pharmingen, San Diego, CA, USA) for GM-
CSF; anti-TNFα mAb (G281-2626; Pharmingen) and a
biotinylated anti-TNFα mAb (MP6-XT3; Pharmingen) for
TNFα; and polyclonal anti-IL-1β Ab and a biotinylated anti-
IL-1β mAb (Endogen, Woburn, MA, USA) for IL-1β. A
streptavidin–horseradish peroxidase conjugate (Pharmin-
gen) followed by TMB-peroxidase substrate (Kirkegaard
and Perry Laboratories, Gaithersburg, MD, USA) was
used to detect the cytokines. A standard curve was con-
structed using serial dilutions of purified GM-CSF, TNFα,
or IL-1β starting at a concentration of 2 ng/ml. Each ELISA
was sensitive down to 15 pg/ml.
Results
GM-CSF blockade prior to onset of arthritis results in less
severe disease
Mice treated i.p. with 300 µg anti-GM-CSF beginning at
day 21 and then every second day until day 31 showed a
decrease in disease severity. The decrease in severity was
seen both as a reduction in the number of affected limbs
per mouse (Supplementary Fig. 1a) and lower clinical
scores for these affected limbs (Supplementary Fig. 1b).
For example, only 1 of 9 (11%) anti-GM-CSF-treated mice
had more than one limb affected compared with 8 of 10
(80%) isotype control-treated mice (P = 0.003) (Supple-
mentary Fig. 1a). Also, none of the affected limbs from
anti-GM-CSF mAb-treated mice had a clinical score of 3
(maximum) compared with 19 individual limbs from isotype
control-treated mice (Supplementary Fig. 1b).
Because continued treatment with anti-GM-CSF was
effective in modifying the disease when initiated at antigen
challenge (i.e. day 21 after primary immunization), the
effect of the addition of anti-GM-CSF mAb at different
times prior to disease onset was examined. Treatment with
anti-GM-CSF mAb on days 21 and 23 resulted in a slight
suppression of the clinical score that was significant on
day 40 (P = 0.044) (Supplementary Fig. 2a). There was,
Arthritis Research    Vol 3 No 5 Cook et alhowever, no significant difference in the incidence, day of
onset, or the number of limbs affected per mouse com-
pared with isotype control-treated mice (data not shown).
Treatment with anti-GM-CSF mAb on day 21 only did not
result in any significant differences compared with isotype
control-treated mice, although there was a trend towards
slightly lower mean clinical scores (Supplementary Fig. 2a).
To assess the effectiveness of treatment with anti-GM-CSF
mAb during the primary induction phase of disease, mice
were treated i.p. with a single injection of 300 µg anti-GM-
CSF mAb at the time of immunization (day 0) (Supplemen-
tary Fig. 2b), or at weekly intervals from the time of
immunization until day 21 (Supplementary Fig. 2c). There
were no significant differences in the mean clinical scores
(Supplementary Fig. 2b,c), the incidence or the day of onset
(data not shown) between mice treated with anti-GM-CSF
mAb and control mAb for either treatment regime. Mice
treated weekly with anti-GM-CSF mAb up to and including
day 21 showed a trend towards slightly lower mean clinical
scores (Supplementary Fig. 2c); findings similar to mice
treated on day 21 (Supplementary Fig. 2a).
GM-CSF blockade prevents the clinical progression of
established arthritis
To further examine the suppression of disease seen in
anti-GM-CSF mAb-treated mice with established disease,
the progression of arthritis in initially affected limbs (Sup-
plementary Fig. 3a) and the recruitment of additional limbs
and their severity, analyzed individually (Supplementary
Fig. 3b), were compared between the anti-GM-CSF mAb-
treated and isotype control-treated groups. The absence
of disease progression was seen as a relative lack of
increase in the clinical score of initially affected limbs
(Supplementary Fig. 3a). For example, the clinical score of
23 of the 33 (70%) initially affected limbs from the anti-
GM-CSF mAb-treated group either did not change or
improved (i.e. a lower score) following treatment, com-
pared with only 9 of the 31 (29%) initially affected limbs
from the control-treated group (P = 0.001). Furthermore,
there was a diminished recruitment of additional limbs
during treatment (Supplementary Fig. 3b). Of note, only 8
of 47 (17%) limbs that were normal at the commencement
of treatment from the anti-GM-CSF-treated group devel-
oped arthritis compared with 23 of 45 (51%) limbs that
were normal from the isotype control-treated group
(P = 0.001). The arthritis that developed in limbs after the
commencement of treatment with anti-GM-CSF mAb was
very mild with a clinical score of only 1 in all cases. The
arthritis that developed in limbs after the commencement
of treatment with the control mAb, however, ranged from
mild (clinical score of 1) to severe (clinical score of 3)
(Supplementary Fig. 3b).
Reduced histopathology of joints following GM-CSF blockade
The cellular infiltration and degree of joint erosion were
quantified from randomly selected mice from each treat-
ment group; 124 joints from 18 hind limbs of anti-GM-
CSF-treated mice and 142 joints from 16 hind limbs of
control-treated mice were examined by microscopy. There
was a significant correlation between the clinical score of
each limb and each histologic feature for both treatment
groups (data not shown).
Humoral and cellular response to CII following GM-CSF
blockade in vivo
Antibodies to CII were measured in serum at the end of
each experiment. Treatment with anti-GM-CSF mAb either
Available online http://arthritis-research.com/content/3/5/293
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Supplementary Figure 1
Effect of anti-GM-CSF treatment prior to the onset of arthritis on individual limb involvement. Data are from the experiment in Fig. 1 where mice
were treated intraperitoneally with either 300 µg anti-GM-CSF or 300 µg isotype control every second day from days 21 to 31. (a) The number of
mice that developed arthritis in a given number of limbs is presented. Anti-GM-CSF (n = 9) versus isotype control mice (n = 10) (P = 0.048; multi-
way chi-squared). There were no anti-GM-CSF-treated mice with all four limbs affected. (b) The number of individual limbs from arthritic mice only
with a particular clinical score (severity) is presented. For the anti-GM-CSF-treated group, n = 20 limbs (5 mice); for the isotype control-treated
group, n = 36 limbs (9 mice). There were no limbs from anti-GM-CSF-treated mice with a clinical score of 3. GM-CSF, Granulocyte macrophage-
colony stimulating factor.
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5post-onset or at various times prior to onset (days 21–31,
day 0, or weekly from days 0 to 21) had no effect on the
anti-CII IgG response (Supplementary Fig. 4a).
CII-specific T-cell expansion was measured in vitro from
mice treated with mAb every second day from days 21 to
31. There was no difference in the proliferative response
of T cells to CII from anti-GM-CSF mAb-treated mice com-
pared with control mAb-treated mice (Supplementary
Fig. 4b). Furthermore, in vitro treatment with anti-GM-CSF
mAb also had no effect on the CII-specific proliferative
response (Supplementary Fig. 4c).
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Supplementary Figure 3
Effect of anti-GM-CSF treatment post-onset on individual limb
involvement. Data are from the experiment in Fig. 2 where mice were
treated intraperitoneally with 300 µg anti-GM-CSF (n = 20 mice) or
isotype control (n = 19 mice) daily from the day of disease onset (day
0) until day 9 (total, 10 times). (a) The progression of arthritis in limbs
already affected prior to the commencement of treatment is presented:
improvement, decrease in clinical score of individual limbs following
treatment; no change, clinical score of individual limbs remained the
same following treatment; mild progression, clinical score of individual
limbs progressed from 1 initially to 2 at the end of treatment;
progression, clinical score of individual limbs progressed from 1 or 2
initially to 3 at the end of treatment (n = 33 limbs [from 20 mice], anti-
GM-CSF-treated group; and n = 31 limbs [from 19 mice], isotype
control-treated group) (P = 0.01; multiway chi-squared). (b) The
number of limbs, initially unaffected (clinical score 0, day 0), that
developed a particular score at the end of the experiment is presented
(n = 47 limbs [from 20 mice], anti-GM-CSF-treated group; and n = 45
limbs [from 19 mice], control-treated group) (P = 0.0007; multiway
chi-squared). There were no limbs recruited in anti-GM-CSF-treated
mice that developed a clinical score > 1. GM-CSF, Granulocyte
macrophage-colony stimulating factor.
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Supplementary Figure 2
Effect of timing of anti-GM-CSF treatment on arthritis development. 
(a) Mice treated on day 21 (n = 17, anti-GM-CSF) or days 21 and 23
(n = 20, anti-GM-CSF; n = 20, isotype control). * Days 21 and 23
treatment, anti-GM-CSF treated versus isotype control treated mice
(day 40) (P = 0.044; Mann–Whitney test). (b) Mice treated at the time
of primary immunization (day 0) only (n = 10, anti-GM-CSF; n = 9,
isotype control). (c) Mice treated at the time of primary immunization
(day 0) then weekly until day 21 (n = 10, anti-GM-CSF; n = 10,
isotype control). For all treatments, 300 µg anti-GM-CSF or isotype
control was used. Results are expressed as the mean ± SEM. GM-
CSF, Granulocyte macrophage-colony stimulating factor.
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Supplementary Figure 4
Effect of anti-GM-CSF treatment on CII-specific immune responses.
(a) IgG Ab response to CII measured at the end of each experiment.
Results are expressed as the mean ± SEM, where the mean level of
anti-CII IgG for isotype control-treated mice was set at 100 U/ml for
each experiment and compared with anti-GM-CSF-treated mice from
the same experiment. (b) Proliferative response to CII measured in
mice treated in vivo with 300 µg of anti-GM-CSF or control mAb from
every second day from days 21 to 31. (c) Proliferative response to CII
measured in mice treated in vivo with control mAb, as in (b), except
cells were cultured in the presence of 100 µg/ml anti-GM-CSF or
control mAb. (b), (c) Results are shown for cells cultured in the
presence of 50 µg/ml CII, and are expressed as a stimulation index
(mean ± SEM) above background readings in the absence of CII
(Stimulation Index = 1). CII, type II collagen; GM-CSF, Granulocyte
macrophage-colony stimulating factor; mAb, monoclonal antibody.
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